A Phase I trial reported in The Lancet shows in-utero stem cell therapy for myelomeningocele is safe and feasible. Placenta-derived mesenchymal stem cells applied during fetal surgery improved healing. For India, with high birth-defect incidence, it may reduce lifelong burdens and support early detection goals of RBSK.
Click to View More
© 2026 iasgyan. All right reserved